




# Investor Fact Sheet

## First half-year 2022/23


(Unaudited Swiss GAAP FER figures)  
in thousand CHF

	Half-year 2022/23	in %	Half-year 2021/22	in %	Change	in %
<b>Sales of goods and services group</b>	<b>244 244</b>	<b>100.0 %</b>	222 588	100.0 %	21 657	9.7 %
Ypsomed Delivery Systems	143 728	58.8 %	118 331	53.2 %	25 396	21.5 %
Ypsomed Diabetes Care	92 013	37.7 %	95 206	42.8 %	-3 194	-3.4 %
Others	8 504	3.5 %	9 050	4.1 %	-546	-6.0 %
Gross profit	65 448	26.8 %	52 342	23.5 %	13 106	25.0 %
<b>Operating profit</b>	<b>19 445</b>	<b>8.0 %</b>	10 489	4.7 %	8 957	85.4 %
Financial income	2 341	1.0 %	1 114	0.5 %	1 228	110.2 %
Financial expenses	-5 048	-2.1 %	-3 035	-1.4 %	-2 013	66.3 %
Income taxes	-1 300	-0.5 %	-1 443	-0.6 %	143	-9.9 %
<b>Net profit</b>	<b>15 439</b>	<b>6.3 %</b>	7 124	3.2 %	8 315	116.7 %
<b>Earnings per share</b> in CHF	<b>1.17</b>		0.56		0.60	107.2 %
Operating profit	19 445	8.0 %	10 489	4.7 %	8 957	85.4 %
Depreciation and impairment of fixed assets	19 865		18 904		961	5.1 %
Amortisation and impairment of intangible assets	17 573		13 036		4 537	34.8 %
<b>EBITDA</b> (operating profit before depreciation and amortisation)	<b>56 883</b>	<b>23.3 %</b>	42 429	19.1 %	14 454	34.1 %
Equity ratio in %	64.4 %		51.9 % <sup>1</sup>		12.5 %	
Investments in fixed assets	54 645		24 154		30 491	126.2 %
Investments in intangible assets	28 310		26 919		1 391	5.2 %
Number of employees	2 047		1 878		169	9.0 %
Number of full-time positions	1 953		1 786		168	9.4 %

### Turnover at group level



### EBIT at group level



<sup>1</sup> As per 31 March 2022.

Further information on significant shareholders and shareholder groups as well as other financial figures of the Ypsomed Group are available in the Semiannual Report 2022/23 and on [www.ypsomed.ch](http://www.ypsomed.ch).

## my life Diabetes Care

With its mylife™ Diabetescare brand, Ypsomed operates successfully in the B2C business with products and services for people with diabetes mellitus. The product portfolio includes: insulin pumps, infusion sets, pen needles, blood glucose monitoring systems and other diabetes supplies. Products are distributed via Ypsomed's subsidiaries to hospitals, doctors, pharmacies and patients, and via distributors (pen needles).

### mylife™ product portfolio (selection)



## Delivery Systems

Our pharmaceutical and biotech customers purchase injection systems and corresponding services under the YDS brand, Ypsomed Delivery Systems. They do this via the industry leader, as Ypsomed is the world's largest developer and manufacturer of pens and autoinjectors with which patients can administer their liquid medication subcutaneously themselves.

Drugs are becoming more specific, e.g. in the treatment of autoimmune diseases. Instead of a generic drug (e.g. Humira®), a large number of new, very specific drugs come onto the market. New drugs for Alzheimer's disease, obesity and rare diseases are being developed. Cancer drugs are also becoming more specific. Efforts to develop active ingredients for subcutaneous injection open up opportunities for self-medication with auto- and patch injectors.

### YDS product portfolio (selection)



**Legal disclaimer:** The information contained in this document has not been independently verified and no representation or warranty, expressed or implied, is made to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein. Neither Ypsomed Holding AG, its advisors or representatives, nor their respective affiliates shall have any liability whatsoever for any loss whatsoever arising from any use of this document, or its content, or otherwise arising in connection with this document. This document does not constitute, or form part of, an offer to sell or a solicitation of an offer to purchase any shares and neither it nor any part of it shall form the basis of, or be relied upon in connection with, any contract or commitment whatsoever. This document contains forward-looking statements which involve risks and uncertainties. These statements may be identified by such words as "may", "plans", "expects", "believes" and similar expressions, or by their context. These statements are made on the basis of current knowledge and assumptions. Various factors could cause actual future results, performance or events to differ materially from those described in these statements. No obligation is assumed to update any forward-looking statements.

### Ypsomed Holding AG

Thomas Kutt, Head Investor Relations // Brunnmattstrasse 6 // 3401 Burgdorf // +41 34 424 35 55 // [thomas.kutt@ypsomed.com](mailto:thomas.kutt@ypsomed.com) // [www.ypsomed.ch](http://www.ypsomed.ch)